FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA's Fast-Track for Rexulti Raises Concerns

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Fast-Track for Rexulti Raises Concerns

FDA rushes approval of dementia drug that quadruples risk of death

Takeda drug gets US FDA priority review status for esophagus

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA Expedited Review Programs - Friends of Cancer Research

FDA's Fast-Track for Rexulti Raises Concerns

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

Norman DeLisle on LinkedIn: Michigan's seven-day average highest

FDA rushes approval of dementia drug that quadruples risk of death

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

WD - June/July 2022 by Lawrence Ambrocio - Issuu